The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Phase I study of CART-ddBCMA in R/R multiple myeloma
Matthew J. Frigault, MD, Harvard Medical School, Boston, MA, discusses the safety and efficacy results of a Phase I study of CART-ddBCMA, an autologous anti-BCMA CAR-T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder, in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
